We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Gracell Biotechnologies Inc | NASDAQ:GRCL | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 10.25 | 10.25 | 10.00 | 0 | 01:00:00 |
Stifel 2023 Healthcare ConferenceFireside Chat: Tuesday, November 14th at 1:15 pm ETOne-on-one meetings: November 14th, 2023Presenter: Dr. Kevin Xie, Chief Financial OfficerLocation: New York
Jefferies London Healthcare Conference Fireside Chat: Wednesday, November 15th at 11:30 am GMT / 6:30 am ETOne-on-one meetings: November 15th and 16th, 2023Presenter: Dr. Kevin Xie, Chief Financial OfficerLocation: London
Piper Sandler 35th Annual Healthcare ConferencePresentation: Tuesday, November 28th at 12:00 pmOne-on-one meetings: November 28th, 2023Presenter: Dr. Kevin Xie, Chief Financial OfficerLocation: New York
6th Annual Evercore ISI HealthCONx ConferencePresentation: Wednesday, November 29th at 9:35 am ETOne-on-one meetings: November 29th and 30th, 2023Presenter: Dr. Kevin Xie, Chief Financial OfficerLocation: Miami
Available webcasts of the presentations will be posted on the News and Events section of the Company's website. A replay of the webcast will be available for 90 days following the event. For more information, please visit ir.gracellbio.com.
About GracellGracell Biotechnologies Inc. (“Gracell”) is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies for the treatment of cancers and autoimmune diseases. Leveraging its innovative FasTCAR and TruUCAR technology platforms and SMART CART™ technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost, and lack of effective CAR-T therapies for solid tumors and autoimmune diseases. The lead candidate BCMA/CD19 dual-targeting FasTCAR-T GC012F is currently being evaluated in clinical studies for the treatment of multiple myeloma, B-NHL and systemic lupus erythematosus (SLE). For more information on Gracell, please visit www.gracellbio.com. Follow @GracellBio on LinkedIn.
Media contact Marvin Tang marvin.tang@gracellbio.com Investor contact Gracie Tong gracie.tong@gracellbio.com
1 Year Gracell Biotechnologies Chart |
1 Month Gracell Biotechnologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions